Cytokinetics EVP sells 11,333 shares after exercise

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction involving company common stock.

Rhea-AI Filing Summary

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction involving company common stock. He exercised 11,333 shares through a non-qualified stock option with a $39.13 per share exercise price, originally exercisable from April 6, 2023 and expiring on March 6, 2033. The same day, he executed an open-market sale of 11,333 common shares at $77.25 per share. Following these transactions, he held 58,555 common shares directly, and the option position showed 13,070 option shares remaining in that grant.

Insider Trade Summary 10b5-1

Exercise and Sale: 11,333 shares ($432K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 11,333 shs ($875K)

Approx. gross sale proceeds $875K

Approx. exercise cost $443K

Approx. pre-tax spread $432K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	11,333	$0.00	$0.00
Exercise	Common Stock	11,333	$39.13	$443K
Sale	Common Stock	11,333	$77.25	$875K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 13,070 contracts (Direct); Common Stock — 58,555 shares (Direct)

Key Figures

Shares sold: 11,333 shares Sale price: $77.25 per share Options exercised: 11,333 shares +5 more

8 metrics

Shares sold 11,333 shares Open-market sale of common stock

Sale price $77.25 per share Price for 11,333 common shares sold

Options exercised 11,333 shares Non-Qualified Stock Option exercise

Option exercise price $39.13 per share Strike price of Non-Qualified Stock Option

Shares held after 58,555 shares Common stock directly owned post-transaction

Options remaining in grant 13,070 shares Non-Qualified Stock Option balance after exercise

Option exercisable date April 6, 2023 Non-Qualified Stock Option became exercisable

Option expiration date March 6, 2033 Non-Qualified Stock Option expiry

Key Terms

Non-Qualified Stock Option, open-market sale, derivative security, exercise price, +1 more

5 terms

Non-Qualified Stock Option financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise price financial

"conversion_or_exercise_price: "39.1300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

direct ownership financial

"ownership_type: "direct" and ownership_code: "D""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTOKINETICS INC (CYTK) report for Andrew Callos?

CYTOKINETICS INC reported that EVP and Chief Commercial Officer Andrew Callos exercised 11,333 stock options and sold 11,333 common shares. The activity was reported on a Form 4 insider trading filing detailing the exercise-and-sell pattern.

How many CYTOKINETICS (CYTK) shares did Andrew Callos sell and at what price?

Andrew Callos sold 11,333 CYTOKINETICS common shares in an open-market transaction at $77.25 per share. This sale occurred on the same date as his stock option exercise, according to the Form 4 disclosure.

What stock options did Andrew Callos exercise in this CYTOKINETICS Form 4?

He exercised 11,333 shares from a Non-Qualified Stock Option with a $39.13 exercise price. The option became exercisable on April 6, 2023 and carries an expiration date of March 6, 2033, as shown in the filing.

How many CYTOKINETICS (CYTK) shares does Andrew Callos hold after these transactions?

After the reported transactions, Andrew Callos directly owned 58,555 CYTOKINETICS common shares. The Form 4 also shows 13,070 option shares remaining in the disclosed non-qualified stock option grant.

Was the CYTOKINETICS (CYTK) transaction by Andrew Callos a net sale or purchase?

The filing reflects a net sale, with 11,333 shares sold after exercising 11,333 options. The transactionSummary in the Form 4 shows a net-sell direction based on the reported share movements.

What is the nature of ownership for Andrew Callos’ CYTOKINETICS shares?

The Form 4 indicates direct ownership for Andrew Callos’ CYTOKINETICS holdings. All reported common stock and option positions in this filing are coded as directly owned by the reporting person, without indirect ownership entities noted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		M		11,333	A	$39.13	69,888	D
Common Stock	05/05/2026		S		11,333	D	$77.25	58,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$39.13	05/05/2026		M			11,333	04/06/2023	03/06/2033	Common Stock	11,333	$0	13,070	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)